Business
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update
Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of Phase 2 CANAL Trial \nCompleted enrollment for Phase 2b/3 PRISM study in chronic pruritus in PN with data expected Q2 2022\nCompleted $55 million private placement in April 2022, proceeds will be used to fund clinical development of Haduvio for the treatment of chronic cough in IPF patients \nManagement to host conference call and webcast today at 4:30 p.m. EDT \nNEW HAVEN, Conn., May 12, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended March 31, 2022, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nTrevi's topline data expected for Ph2b/3 PRISM study this quarter and full results for Ph2 CANAL study in Q3\"We are delighted with the significant progress made this year in achieving Trevi's clinical development goals and the advancement of Haduvio,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"The interim analysis results of the Phase 2 CANAL study allowed us to end enrollment early in the trial and begin preparations to accelerate development for this indication.\"\nMs. Good added, \"Additionally, the successful closing of a $55 million private placement on April 11, 2022, allows us to fund the next phase of development for Haduvio in chronic cough in IPF. We look forward to our expected data readout for the Phase 2b/3 PRISM study this quarter and the data readout from the full set of subjects for the Phase 2 CANAL study in the third quarter of this year.\"\nKey Business Updates\nPhase 2 CANAL trial of Haduvio for chronic cough in patients with IPFConcluded enrollment early for its Phase 2 Cough And NALbuphine (CANAL) trial for the treatment of chronic cough in IPF patientsStatistically significant efficacy results from the interim analysis (N=26) were announced:The primary efficacy endpoint demonstrated a 77.3% reduction in daytime cough frequency from baseline with the use of Haduvio compared to a 25.7% reduction with placebo, demonstrating a 52% placebo-adj...